Corbus Pharmaceuticals announced positive Phase 1b CANYON-1 trial results for its oral obesity candidate, CRB-913. The study of 254 participants showed a 5.0% mean weight loss at the 60 mg dose after 12 weeks, with a favorable safety profile and an 8.3% discontinuation rate due to adverse events. The company plans to engage with the FDA to discuss future development paths for the non-incretin therapy.
The 8-K discloses Phase 1b CANYON-1 data showing statistically significant weight loss at all doses of CRB-913, with 5.0% LS mean weight loss at 60 mg after 12 weeks (p<0.0001) versus 0.0% on placebo, and an 8.3% discontinuation rate due to adverse events. Positive obesity trial data with a clean safety profile is a direct value driver for a clinical-stage company like Corbus. The 5% magnitude is modest versus injectable GLP-1s, but the oral, non-incretin profile and no plateauing across doses support further development.
- ▲ Phase 1b data presented at ObesityWeek on November 16, 2026: 5.0% weight loss at 60 mg vs 0.0% placebo, p<0.0001
- ▲ Discontinuation rate due to AEs of 8.3%, in line with published GLP-1 data
- ▼ 5% weight loss at 12 weeks is modest relative to established incretin therapies
- ▼ Phase 1b trial of 254 participants over 12 weeks; results need confirmation in later-stage trials